1 2	Enhanced Gut Microbiome Capacity for Amino Acid Metabolism is associated with Peanut Oral Immunotherapy Failure
3 4	Mustafa Özçam ¹ , Din L. Lin ¹ , Chhedi L. Gupta ^{1,2,#} , Allison Li ¹ , Lisa M. Wheatley ³ , Carolyn H.
5	Baloh ^{4,5,6} , Srinath Sanda ⁷ , Stacie M. Jones ⁸ , Susan V. Lynch ^{1*}
0 7	
8	¹ Division of Gastroenterology, Department of Medicine, University of California, San Francisco,
9	San Francisco, CA, USA
10 11	² Benioff Center for Microbiome Medicine, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA
12	³ National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda
13	MD. USA.
14	⁴ The Immune Tolerance Network, Boston, MA, USA
15	⁵ Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, MA,
16	USA
17	⁶ Harvard Medical School, Boston, MA, USA
18	⁷ The Immune Tolerance Network, San Francisco, CA, USA
19	⁸ Division of Allergy and Immunology, Department of Pediatrics, University of Arkansas for
20	Medical Sciences and Arkansas Children's Hospital. Little Rock, AR, USA
21	······································
22	[#] Present Address: ICMR-National Institute of Immunohaematology, Chandrapur Unit
23	(ICMR-CRMCH), Maharashtra, India
24	
25	*Corresponding author: susan.lynch@ucsf.edu
26	
27	Abstract
28	
29	Peanut Oral Immunotherapy (POIT) holds promise for remission of peanut allergy, though
30	treatment is protracted and successful in only a subset of patients. Because the gut microbiome
31	is linked to food allergy, we sought to identify fecal microbial predictors of POIT efficacy and to
32	develop mechanistic insights into treatment response. Longitudinal functional analysis of the fecal
33	microbiome of children (n=79) undergoing POIT in a first double-blind, placebo-controlled clinical
34 25	trial, identified five microbial-derived bile acids enriched in fecal samples prior to POIT initiation
33 26	that predicted treatment efficacy (AUC 0.71). Failure to induce disease remission was associated
30 27	with a distinct fecal microbiome with enhanced capacity for bile acid deconjugation, amino acid
38	of POIT failure appear to include depletion of immunomedulatory secondary bile and amine acids
30	and the antigenic peanut pentides pecessary to promote peanut allergy desensitization and
40	remission
41	
42	
43	Keywords. Peanut Allergy, Oral Immunotherapy, Gut Microbiome, Metabolome, Bile Acids.

44 Main

45 Peanut protein allergy (PA) is a life-threatening condition affecting 2% of the population in industrialized nations¹. A leading cause of food-induced anaphylaxis², the condition was not 46 treatable until the approval of peanut oral immunotherapy (Palforzia[™]) by the U.S. Food and Drug 47 48 Administration in 2020, with strict avoidance of peanuts and peanut-containing products 49 representing the most effective disease management strategy³. Peanut oral immunotherapy 50 (POIT) has emerged as a treatment that is widely utilized for PA⁴. Gradual oral introduction of 51 increasing concentrations of peanut product induces desensitization, defined as an increase in 52 reaction threshold while on treatment, in approximately 50-70% of treated patients. While POIT 53 has demonstrated efficacy in desensitizing patients to peanut, the induction of remission, defined 54 as the prolonged absence of clinical reactivity after treatment cessation, is observed in a smaller subset of approximately 20-30% of POIT-treated patients⁴⁻⁶. The cost, prolonged duration (years), 55 56 and burden of daily treatment associated with POIT highlight the need for improved predictive 57 biomarkers and adjunctive treatments to increase efficacy.

58

59 The IMPACT, Oral Immunotherapy for the Induction of Tolerance and Desensitization in 60 Peanut-Allergic Children trial (NCT01867671) was the first randomized, double-blinded, placebocontrolled, multicenter clinical trial to evaluate the efficacy and safety of POIT in peanut-allergic 61 62 children ages 12-48 months old. While 71% of the children receiving POIT achieved 63 desensitization, only 21% of children achieved remission following POIT discontinuation and 26-64 weeks of peanut avoidance. The IMPACT trial yielded three clinical outcomes among peanutallergic children treated with POIT: i) those who achieved both desensitization and remission 65 66 (D+R+), ii) those who achieved only desensitization but not remission (D+R-), iii) those who did 67 not achieve desensitization or remission (D-R-). Notably, younger age and lower peanut-specific 68 serum IgE concentrations at the outset of the trial were more likely to result in a D+R+ outcome⁷. 69 Both age⁸ and allergic sensitization status⁹ are closely related with early life gut microbiome composition and metabolic activity¹⁰. Thus, we hypothesized that gut microbiome functional 70 71 features at baseline are associated with both POIT-induced clinical outcomes and peanut IgE 72 levels, and that longitudinal assessment of fecal microbiomes from children in this trial would 73 reveal mechanisms underlying variance in POIT efficacy.

74

75 **Results**76

77 Study Population and Clinical Trial Outcomes

78

Details of the IMPACT trial design and outcomes have been published previously⁷. Briefly, 79 80 at baseline, 146 peanut-allergic children were randomized (2:1) to either POIT or placebo 81 treatment. After a dose escalation phase of 30-weeks, children in the POIT arm received 2,000 82 mg peanut protein (lightly roasted, partly defatted [12% fat]) while the placebo group received oat 83 flour for 104 weeks (total blinded treatment period 134 weeks). Participants who passed the 5-g 84 peanut protein, double-blind, placebo-controlled, food challenge (DBPCFC) at the end of 85 treatment (week 134) were categorized as desensitized (D+). Independent of the DBPCFC 86 outcome at week 134, all participants avoided peanut consumption for 24 weeks (avoidance 87 period), and those who passed the 5-g peanut protein DBPCFC at the end of this avoidance

88 period (week 160) were categorized as being in remission (R+). A total of 327 longitudinal fecal 89 samples from 79 participants (Table S1) were collected at baseline (prior to POIT initiation), end 90 of buildup (EoB), mid maintenance (MM), end of treatment (EoT), and the end of avoidance (EoA 91 Fig. 1A; Table S1). Participant baseline characteristics including age, sex and study locations 92 are reported in Table S2. Based on DBPCFC results at the end of treatment and end of 93 avoidance, the IMPACT clinical trial yielded three outcome groups, Desensitized and Remission 94 (D+R+), Desensitized and no remission (D+R-) and no desensitization and no remission (D-R-; 95 Fig. 1A).

96 97

Gut microbiota composition associates with peanut oral immunotherapy outcomes.

98

99 The subgroup of IMPACT trial participants analyzed in our study (n=79 of 146) did not 100 differ in age between POIT and placebo-treated groups (Extended Data Fig. 1A). Consistent with 101 observations made in the parent clinical trial⁷, within the POIT-treated group, D+R+ participants 102 were significantly younger compared to those within the two other outcome groups (D+R- and 103 D-R-; Extended Data Fig. 1B). These data indicate that the subset of participants used in the 104 current study is representative of the overall trial population. To identify potential confounding 105 factors in our study, we initially examined relationships between variables captured in the study 106 population and 16S rRNA sequencing-based gut microbiota profiles generated on all available 107 longitudinally collected fecal samples (n=277 [Placebo, n=87; POIT, n=190] following quality 108 filtering and rarefaction; see methods section for details). As expected, bacterial community α -109 diversity (number of taxa and their distribution) increased with advancing participant age at 110 screening (Pearson's correlation, r=0.42, P<0.0001; Extended Data Fig. 1C). To identify other 111 potential confounding factors, clinical and demographic variables were examined as independent 112 terms at each time point using *PERMANOVA* based on an unweighted UniFrac distance matrix. 113 Importantly, POIT outcomes (P=0.008, $R^2=0.07$, n=47) and specifically remission outcome 114 (P=0.003, $R^2=0.04$, n=47) related to variance in gut microbiota composition only at baseline prior 115 to POIT initiation, suggesting that gut microbiome composition prior to treatment associates with 116 clinical outcomes. Additionally, age at screening, sample collection date, sex, and study site 117 location significantly related to variance in gut microbiota composition at various time points 118 throughout the trial (Table S3). Thus, subsequent statistical analyses performed were adjusted 119 for these covariates (see method section for details).

120 121

122 Children who develop POIT-induced remission exhibit a distinct gut microbiome 123 throughout the course of the trial.

124

125 Comparing bacterial phylogenetic diversity (α -diversity) and composition (β -diversity) over 126 time revealed no significant difference between the POIT and placebo arms at any time point 127 (**Extended Data Fig. 1D and 1E**), indicating that POIT does not appreciably alter fecal microbiota 128 composition. However, within the POIT-treated group, the three distinct outcome groups exhibited 129 significant differences in fecal microbiota α - (**Fig. 1B**) and β -diversity that were evident at baseline 130 and sustained throughout the course of the trial (*P*<0.001, *R*²=0.029, *n*=127, Linear Mixed Effect; 131 **Fig. 1C**). Specifically, the D+R+ group exhibited significantly lower α -diversity compared to D+R-

and D-R- groups (*P*=0.001 and 0.052, respectively; Wilcoxon rank-sum test); this finding remained significant following adjustment for age (*P*=0.043 ANOVA; **Fig. 1B and Extended Data Fig. 1F and G**). Additionally, throughout the course of the trial, participants who achieved remission (D+R+) exhibited significant differences in gut microbiota composition along the first principal component (axis 1) compared to those who did not (D+R+ vs D+R-, *P*=0.03; D+R+ vs D-R-, *P*=0.003, Linear Mixed Effect; **Fig. 1C**). This provided evidence that both gut microbiota composition and diversity are associated with POIT outcomes within the trial participants.

139

In the parent IMPACT trial, baseline concentrations of peanut-specific serum 140 141 Immunoglobulin E (IgE) were predictive of remission⁷. We thus determined whether fecal 142 microbiota features related to IgE levels in POIT-treated children. In age-adjusted analyses, 143 significant positive correlations between α -diversity and serum levels of total IqE (**Fig. 1D**). 144 peanut-specific lqE (Fig. 1E) and Ara h 2-specific lqE (Fig. 1F; P<0.05 Pearson correlation for 145 all) were observed, suggesting that increased fecal diversity relates to higher IgE levels that are 146 associated with reduced likelihood of remission following POIT. Since both younger age and lower 147 baseline peanut-specific IgE levels predicted clinical remission in the IMPACT trial, we next 148 identified baseline bacterial Sequence Variances (SVs) associated with both peanut-specific IgE 149 level and remission status in age-adjusted analyses. Romboutsia ilealis/timonensis was 150 associated with POIT-induced remission, while Ruminococcaceae along with Parabacteroides 151 distasonis, and Oscillospirales members were associated with failure to develop remission 152 (P.FDR<0.05. generalized additive mix models, adjusted for age. Fig. 1G). R. ilealis/timonensis 153 was also negatively associated with peanut-specific IgE levels at baseline (P.FDR<0.05. 154 generalized additive mix models, adjusted for age. Table S4 & Fig. 1H) and with all component-155 specific Ara h-specific IgEs (Ara h 1, 2, 3 and 6 IgEs; Extended Data Fig. 1H). However, no 156 significant difference in relative abundance of any SVs was observed when longitudinal analyses 157 were performed to determine whether these findings in baseline samples were sustained through 158 the course of the trial. Thus, 16S rRNA-based microbiota profiling provided initial evidence that 159 gut microbiota phylogenetic diversity and composition prior to POIT initiation relate to treatment 160 outcomes, and that the abundance of select gut microbial members associate with multiple 161 measures of peanut allergic sensitization irrespective of participant age.

162

163 Baseline bile acid profile associates with POIT efficacy outcomes

164

165 Distinct early-life fecal microbiome compositions associate with subsequent allergic 166 disease development and exhibit discrete metabolic profiles that can induce allergic inflammation *in vitro*¹¹. Additionally, relationships between fecal metabolite profile and food allergy have been 167 previously described in humans¹²⁻¹⁵ and gut microbiomes are known to modulate host immunity 168 169 through the production of metabolites, including those that can affect immunotherapy efficacy^{16,17}. 170 To determine whether the distinct fecal microbiota compositions associated with POIT outcomes 171 exhibited divergent metabolic profiles, untargeted metabolomic analyses was performed on fecal 172 samples collected at baseline, end of treatment, and end of avoidance from study participants 173 (n=58 samples per visit) with sufficient available remaining sample for analysis at all three time 174 points (Table S1 and Fig. 1A). Like gut microbiota composition, baseline fecal metabolite profile

was associated with POIT outcome groups (n=43, $R^2=0.07$, P=0.01), and with remission status (n=43, $R^2=0.04$, P=0.01; *PERMANOVA*, Euclidean distance matrix, **Supplementary Table S5**).

177

178 To identify metabolites that relate to POIT outcomes, a data reduction approach, weighted 179 gene correlation network analyses (WGCNA), was applied to identify modules of co-associated 180 metabolites which were then related to POIT outcomes. Fifty metabolite modules (Untargeted 181 Metabolite Modules [UMMs]; Table S6) were identified, 16 of which associated with POIT 182 outcomes at baseline, end of treatment, or end of avoidance (P < 0.05 ANOVA, adjusted for age; 183 Fig. 2A). The majority of the outcome associated metabolic modules at baseline were elevated 184 in those who did not achieve remission (Extended Data Fig. 2A) and included multiple lipid-185 containing modules, in particular bile acid and amino acid containing modules that distinguished 186 D+R+ from D+R- and D-R- groups (Fig. 2A). Further supporting these observations, bile acid 187 profiles significantly differed between POIT-outcome groups at baseline (Fig. 2B; n=43, $R^2=0.10$, 188 P=0.015, PERMANOVA Euclidean distance matrix), but not at the end of treatment or avoidance 189 (Extended Data Fig. 2B), suggesting that the specific profile of bile acids present at the initiation 190 of POIT influences treatment outcomes.

191

192 At baseline, two modules (UMM10 and UMM15) comprised primarily of unconjugated or 193 conjugated secondary bile acids respectively, exhibited opposing relationships with POIT-induced 194 remission (Fig. 2C & Fig. 2D). The module of unconjugated bile acids i.e. those lacking amino 195 acid conjugates, was increased in those who did not achieve POIT-induced remission (Fig. 2F). 196 A distinct group of secondary bile acids from UMM15 (Fig. 2G) and UMM4 (Fig. 2E & Fig. 2H) 197 including tauroursodeoxycholic acid sulfate, glycoursodeoxycholic acid sulfate and 198 taurolithocholate 3-sulfate were depleted in the feces of children who did not develop remission. 199 Bile acids, produced by the liver are transformed into secondary bile acids exclusively by the gut 200 microbiome¹⁸. They play crucial roles in dietary lipid absorption, regulation of lipid, glucose and 201 xenobiotic metabolism¹⁹ and protect against bacterial overgrowth¹⁸. The secondary bile acids 202 enriched in those who achieved remission are known to have anti-inflammatory properties and in 203 the case of taurolithocholate, capable of down-regulating macrophage inflammatory response to 204 antigenic stimulation²⁰.

205

206 Since bile acids are drivers of out microbiota maturation in early life^{21,22}, we next 207 investigated whether relationships existed between the bile acid modules UMM10 and UMM15 208 and gut microbiota features that associated with POIT outcomes. Specifically, the eigenvector (a 209 measure of the joint abundance profile of a specific module) of UMM15, primarily comprised of 210 bacterial-derived secondary bile acids (Supplementary Table S6), exhibited a significant 211 negative relationship with fecal microbiota α -diversity (lower baseline α -diversity is associated 212 with POIT-mediated remission; Fig. 1B) and a positive correlation with axis 1 of the baseline 213 microbiota composition. In contrast the unconjugated bile acid module (UMM10) exhibited the 214 opposite relationship, being positively correlated with fecal α -diversity and negatively correlated 215 with axis 1 of the baseline microbiota composition (Extended Data Fig. 2C). These data suggest 216 that at baseline, secondary bile acids associate with the lower gut bacterial diversity (Fig. 1B) and 217 a distinct gut bacterial composition (Fig. 1C) that characterize children who develop POIT-induced 218 remission.

219

220 Notably, bile acid modules that differentiated POIT outcome groups at baseline were not 221 associated with clinical outcomes at the end of treatment or avoidance samples (Fig. 2A). 222 Nonetheless, we rationalized that specific bile acids within these modules may continue to 223 differentiate outcome groups at later time points. Leveraging generalized additive mixed models 224 on longitudinal metabolomics samples, the UMM10 unconjugated bile acid, glycodeoxycholate 225 was found to be in significantly higher concentrations in the feces of children for whom POIT-226 failed to induce remission throughout the course of the trial (P=0.021; Supplementary Table S8). 227 Notably, glycodeoxycholate promotes innate lymphoid cell 3 secretion of IL-22²³, which can 228 reduce systemic absorption of peanut allergens by increasing intestinal barrier integrity, resulting 229 in reduced antigen presenting cell encounters with peanut antigens²⁴. These data indicate that 230 significant differences in bile acid profiles exist between POIT outcome groups, particularly in 231 baseline samples, and that glycodeoxycholate, which is known to reduce antigen exposure 232 remains significantly elevated over time in the feces of those who fail to achieve remission 233 following POIT treatment.

234

Fecal microbiomes of non-remitting patients exhibit increased gluconeogenesis, anaerobic energy metabolism and amino acid metabolism

237

To investigate gut microbial pathways associated with POIT outcomes, shotgun 238 239 metagenomic sequencing was performed on baseline (n=76) end of treatment, (n=54), and end 240 of avoidance (n=55) samples (Fig. 1A), including all samples that had undergone parallel 241 untargeted metabolomic analysis. Application of WGCNA to shotgun metagenomic data identified 242 45 shotgun metagenomic modules (SMMs; Supplementary Table S9), seven of which 243 significantly associated with POIT outcomes (four at baseline and three at end of treatment (Fig. 3A, ANOVA, P<0.05, adjusted for age). At baseline, POIT-associated shotgun metagenome 244 245 modules (SMMs) were primarily related to microbial growth (SMM6), energy metabolism 246 (SMM26), peptidoglycan (SSM10), and phospholipid biosynthesis (SMM11), while at the end of 247 treatment, long chain fatty acid production (SMM33) and gluconeogenesis and anaerobic energy 248 metabolism (SMM43) differed across the three outcome groups (P<0.05, ANOVA, adjusted for 249 age; Fig. 3A).

250

251 The gluconeogenesis and anaerobic energy metabolism module (SMM43), which was 252 enriched in children who failed to develop POIT-induced remission at the end of avoidance 253 (Extended Data Fig. 2E), was significantly correlated with 12 of the 16 metabolite modules 254 (module eigengenes) associated with POIT outcomes (Pearson correlation, P<0.05; Fig. 3B). This 255 included a positive correlation with the module of unconjugated bile acids (UMM10) and negative 256 correlations with the secondary bile acid module (UMM15) and three remission-associated amino acid modules (UMM4, UMM5, and UMM43; Fig. 3B) that were decreased in non-responders 257 258 (Extended Data Fig. 2D). These data provide evidence that a fecal microbiome primarily 259 engaged in alternate pathways of glucose production from non-carbohydrate sources and 260 anaerobic metabolism contributes to the observed bile acid deconjugation and amino acid 261 depletion in participants who fail to achieve POIT-induced remission.

263 To validate these observations, we performed a secondary, integrative data analysis on 264 longitudinal metagenomic and paired metabolomic datasets using Multi-Omics Factor Analyses 265 (MOFA2) which identified seven distinct factors (Extended Data Fig. 3A), five of which 266 significantly differentiated POIT response groups (ANOVA, P<0.05; Fig. 3C & Extended Data 267 Fig. 3B). Consistent with our findings, several of these factors included microbial pathways for 268 amino acid biosynthesis that were enriched in those who achieved POIT-induced remission. One 269 factor (Factor 2) included Gluconeogenesis and Anaerobic Energy Metabolism amongst the top 270 five microbial pathways within this factor (Fig. 3C, Extended Data Fig. 3C), which were enriched 271 in the fecal microbiome of children who did not develop POIT-induced remission (Extended Data 272 Fig. 3B). In addition, secondary bile acid metabolites including 7-ketodeoxycholate, 7-273 ketolithocholate, chenodeoxycholate were amongst the top 5 metabolites in Factor 2, all of which 274 were depleted in the no remission group (Fig. 3E). Together, these data validate that microbial 275 gluconeogenesis and anaerobic metabolism relates with changes in the profile of secondary bile 276 and amino acids that associate with POIT efficacy.

277

278 To assess whether the top five secondary bile acids from Factor 2, which were all 279 increased in the remission groups at baseline, could serve as a predictive marker for POIT-280 induced remission, a machine learning approach with logistic regression model was employed. 281 The baseline abundance of these five metabolites produced a moderate predictive ability (area 282 under the curve (AUC) from 100 times repeated five-fold cross-validation, measured as mean 283 AUC ± standard deviation (s.d.: AUC_{logistic regression}: 0.712 ± 0.081; Fig. 3F). To confirm our findings, 284 a second machine learning model with random forest was employed and demonstrated similar 285 performance (Extended Data Fig. 3E).

286

287 Enhanced Microbiome Amino Acid Metabolism Associates with Failure to Induce288 Remission.

289

290 At the end of avoidance, the majority of POIT-associated metabolite modules (five out of 291 eight) were primarily comprised of amino acids (Fig. 2A, Supplementary Table S6). Several of 292 these (UMM4, 5, 17 and 42) were decreased in children for whom POIT failed to induce 293 desensitization and remission (D-R-; Extended Data Fig. 2D). Notably, amino acid profiles were 294 significantly different among POIT outcome groups at baseline (n=43, $R^2 = 0.08$; P = 0.006; Fig. 295 **4A**) and end of avoidance (n=43, $R^2 = 0.07$; P = 0.039, Fig. 4B), but not at the end of treatment 296 (PERMANOVA analyses, Extended Data Fig. 3F), suggesting that differences in dietary amino 297 acid intake and/or microbial amino acid metabolism differentiate those who do or do not develop 298 remission in response to POIT.

299

Moreover, at end of avoidance, POIT response-associated metabolite modules contained a total of 117 amino acids and their derivatives, 68 of these belonged to UMM4 (**Table S6**), which was significantly reduced in the D-R- group (**Extended Data Fig. 2D**). The majority of these amino acid metabolites' abundances were decreased in relative concentration in the feces of children who failed to achieve remission (**Fig. 4C**) Notably, increased concentrations of microbial-derived branched-chain amino acid fermentation end products such as skatol and indole²⁵ were evident in both the D+R- and D-R- groups (**Fig. 4C**) indicating that the observed reduction in amino acid

307 concentrations is due to increased microbial amino acid utilization capacity in those who failed to308 achieve POIT-induced remission.

309

Amino acids represent a major energy source for anaerobic gut bacteria²⁶, and select 310 microbes are capable of harvesting amino acids by deconjugating primary bile acids²⁷. Decreased 311 312 fecal amino acid concentrations and increased anaerobic energy and gluconeogenesis 313 metabolism in POIT-treated children who failed to achieve remission prompted us to investigate 314 whether their gut microbiomes encoded a distinct or enhanced capacity for amino acid utilization. 315 Using generalized additive mixed models on longitudinal microbial pathway abundance data, we 316 found that the microbial pathways associated with amino acid metabolism including L-histidine 317 degradation, anerobic energy metabolism, L-citrulline biosynthesis (Arginine degradation), and 318 gluconeogenesis (which uses non carbohydrate sources, including amino acids for energy 319 production²⁸) were enriched in the gut microbiomes of children who did not achieve remission. In 320 contrast, and consistent with metabolite modules associated with remission, D+R+ children 321 possessed fecal microbiota that encoded pathways involved in amino acid biosynthesis 322 (generalized additive mix model, P<0.05, but P.FDR>0.05; Fig. 4D & Table S8). These data 323 indicate that gut microbiomes with enhanced capacity for gluconeogenesis and amino acid 324 metabolism, result in depletion of immunomodulatory amino and secondary bile acids that 325 associate with POIT failure.

326

327 Because peanut antigen exposure is critical to develop immunological tolerance to 328 peanut^{3,29} and children who failed to achieve remission exhibited a gut microbiome with enhanced 329 capacity for amino acid metabolism (Fig. 4D), we hypothesized that their gut microbiome may 330 also have increased capacity for peanut metabolism, effectively reducing available antigen. To 331 test this, stabilized in vitro fecal microbiome cultures from participants in each of the outcome 332 groups (D+R+, n=12, D+R-, n=12, D-R-, n=12) were developed as previously described³⁰ and co-333 incubated with peanut extract under anaerobic conditions prior to Ara h 2 guantification by ELISA. 334 Fecal microbiomes of all participants, regardless of remission outcome, exhibited the capacity to 335 metabolize Ara h 2 peptides, one of the most proteolysis-resistant peanut protein antigens³¹. 336 However, the microbiome of those who failed to achieve remission exhibited a significantly 337 increased capacity to metabolize Ara h 2 peptides compared to those who achieved remission, 338 indicating that enhanced microbial metabolism of allergenic peanut peptides associates with POIT 339 failure (Fig 4E).

340

341 Discussion

342

343 Integrated analyses of 16S rRNA data generated from fecal samples longitudinally 344 collected from IMPACT participants (Placebo, n=87; POIT, n=190) provide evidence that 345 microbial activities in the fecal microbiome prior to POIT initiation relate to treatment outcomes. 346 The data also indicate that the composition of the gut microbiome is distinct over a three-year 347 treatment period in those who do or do not experience peanut allergy remission following POIT, 348 suggesting that microbial-mediated changes in immune function are associated with distinct 349 trajectories of microbiome development and POIT outcomes in study participants. Functional 350 analyses of fecal microbiomes indicate that bile acids, specifically secondary bile acids enriched

351 in baseline samples, associate with POIT-induced remission. Microbial-derived secondary bile 352 acids serve as hormones that regulate cholesterol metabolism and influence energy balance via nuclear and G-protein-coupled receptors^{32,33} that also shape innate immune response^{34,35}. 353 Studies have demonstrated that the bile acid pool regulates colonic FOXP3+ regulatory T (Treg) 354 cells that express the transcription factor RORy³⁶. Bile acids found to be increased in baseline 355 356 samples of participants who experienced peanut allergy remission in our study are known to have 357 allergy protective effects; for example, tauroursodeoxycholic acid attenuates allergic inflammation by inhibiting unfolded protein response transducers³⁷. 358

359

360 Children for whom POIT failed to induce remission exhibit a significantly distinct gut 361 microbiome, enhanced for gluconeogenesis and anaerobic metabolism, indicating that these gut 362 microbiomes derive energy from alternative non-carbohydrate substrates. Our data indicate that 363 the gut microbiome of these children is enhanced for amino acid metabolism. Evidence for this 364 comes from the increased pools of deconjugated (primary) bile acids and a significant depletion 365 of secondary bile and amino acids in the feces of these children. Primary bile acids are most 366 commonly conjugated to the amino acids glycine and taurine to produce glycocholic and 367 taurocholic acids respectively¹⁸, which are subsequently converted to immunoregulatory 368 secondary bile acids by colonic bacteria¹⁸. Primary bile acids, specifically chenodeoxycholic acid, 369 was recently shown to promote food sensitization via activation of a retinoic acid response 370 element in dendritic cells, to promote food allergen specific IgE and IgG1³⁸. Enhanced colonic 371 microbial capacity to harvest amino acids from conjugated bile acids results in increased 372 concentrations of the deconjugated forms, essentially reverting them back to their primary bile 373 acid state. Thus, our findings indicate that a gut microbiome that primarily derives energy from 374 amino acid fermentation results in the depletion of immunomodulatory amino and secondary bile 375 acids both of which associate with POIT remission failure.

376

377 It is well established that peanut allergen exposure is critical to build tolerance and prevent 378 allergy development³. Our data suggests that a second microbial-derived mechanism of POIT 379 failure appears to involve reduced peanut antigen exposure. Food allergies and intolerances are 380 typically driven by specific protein motifs in foods such as Ara h peptides in peanuts, casein and 381 beta-lactoglobulin in cow's milk and tropomyosin proteins in shellfish³⁹. Ingested allergens 382 typically undergo enzymatic breakdown in the oral cavity, stomach, and small intestine⁴⁰ prior to interacting with antigen-presenting cells⁴¹. However, certain key antigenic peanut peptides e.g. 383 384 Ara h 2 peptides, are highly resistant to proteolysis⁴², making it likely that they survive transit 385 through the upper gastrointestinal tract to the distal colon. The extent of peanut protein digestion 386 determines the concentrations and profile of antigenic peptides available for presentation by 387 antigen presenting cells. Our data indicates clear differences in amino acid metabolism capacity 388 and peanut degradation in participants who did or did not achieve remission suggesting that 389 differences in distal gut microbial protein catabolism may impact the quantity and profile of 390 antigenic peanut peptides available to promote tolerance development.

391

392 Gut microbial protein metabolism has never been explored in the context of food allergy, 393 particularly related to treatment-induced efficacy outcomes. Elucidating the impact of gut 394 microorganisms on allergic food proteins may pave the way to develop more effective

immunotherapeutic approaches either by targeting gut microbiome functions or by protecting immunotherapeutic peanut proteins from microbial metabolism by encapsulating them in foodgrade colloidal systems. A similar encapsulation system for gluten immunotherapy is currently being tested in several clinical trials^{43,44}, which so far have demonstrated safety and efficacy. Our study highlights the potential role of the gut microbiome in POIT efficacy outcomes and suggests that it could serve as both a prognostic biomarker to identify those for whom POIT may be most successful and as a therapeutic target to improve rates of POIT-induced remission.

- 402
- 403

404Materials and Methods405

406 407

Clinical trial description and study population

408 409 Full details of the IMPACT clinical trial (NCT01867671) have been previously described⁴⁵.

410 Sample collection, DNA extraction, 16S rRNA library preparation and sequencing

411

412 Stool samples were collected from participants at home and stored at clinical collection 413 sites at -80 °C. Three hundred twenty-seven samples (n=327) were shipped to the University of 414 California San Francisco (UCSF), on dry ice, where they were also stored at -80 °C until 415 processed. Investigators of this study were blinded and did not have access to the metadata until 416 initial 16S rRNA data generation. Thus, all 327 samples were included for 16S rRNA sequencing. 417 Three hundred two (302) samples generated 16S rRNA data since some samples failed PCR 418 amplification or did not pass quality filtering and rarefaction during 16S rRNA analyses. Two 419 hundred seventy-seven (277) out of 302 samples belonged to participants that completed the 420 POIT trial until the end of the avoidance, and therefore, they were used in 16S rRNA data 421 analyses.

422

DNA was extracted from all stool samples using a modified cetyltrimethylammonium 423 424 bromide (CTAB) buffer extraction protocol as previously described^{11,46}. The variable region 4 (V4) 425 of the 16S rRNA gene was amplified using 1 ng μ ⁻¹ of DNA template using 515F and 806R primer 426 pairs as previously described⁴⁷. Amplicon concentrations were normalized using SequalPrep[™] 427 Normalization Plate Kit (Thermofisher Scientific), guantified using the Qubit 2.0 428 Fluorometer and the dsDNA HS Assay Kit (Life Technologies) and pooled at 5 ng per sample 429 which was purified using AMPure SPRI beads (Beckman Coulter). 2 nM of library was spiked with 430 30% of PhiX control v3 (Illumina). The denatured libraries and PhiX were diluted to 20 pM, and 431 1.5 pM were loaded onto the Illumina NextSeg 500/550 v2.5 High Output cartridge.

432

433 Sequence data was processed as previously described⁴⁸. Forward and reverse reads 434 were demultiplexed by using Quantitative Insights Into Microbial Ecology (QIIME 1.9.1)⁴⁹. 435 Samples sequences with more than two bases having a Q-score less than 30 were truncated. As 436 recommended by the Divisive Amplicon Denoising Algorithm 2 (DADA2) v1.16 protocol in R with 437 the following modifications: Reads were maintained if they exhibited a maximum expected error 438 of two and a read length of at least 150 base pair (bp) using the *filterAndTrim* function in the *dada2*

package⁵⁰. Reads were dereplicated and errors were learned on 1×10^8 reads, from samples 439 440 chosen at random. Finally, chimeras were identified using the "consensus" method. Paired reads 441 were merged with a minimum overlap of 25 bp, and reads were aggregated into a count table. 442 Any V4 sequences abnormally short or long $(\pm 5 \text{ bp from the most frequently observed bp length};$ 443 here: 253 bp) were also removed. We assigned taxonomic classifications to Sequence Variants 444 (SVs) using assignTaxonomy in the dada2 package and an 80% bootstrap cutoff, utilizing the SILVA v132 database⁵¹, and species identification with assignSpecies at 100% identity. All 445 446 species achieving an exact match were recorded, and the first in the list was used for descriptive 447 purposes. Once these steps were completed for each run, all runs were combined into a complete 448 SV table. A phylogenetic tree was constructed using phangorn^{52,53} and DECIPHER packages⁵⁴. 449 The SV table was then filtered only to variants belonging to the kingdom Bacteria. Variants were 450 also removed if they were present in less than 0.001% of the total number of observed sequences 451 reads. Next, we employed methods to remove potential contaminants based on SVs present in 452 negative controls. Specifically, SVs were removed if they were present in greater than 15% of the 453 negative controls and less than 15% of the samples⁴⁸ (primarily *Pseudomonas* SVs). For the 454 remaining sequence variants in negative controls, the mean of the read count for each was 455 calculated, rounded upward to the nearest whole number and subtracted for each of these SVs 456 in the dataset. Any remaining negative control SVs were subtracted from samples using the 457 maximum read count across negative controls. Data was representatively rarefied at 35,000 reads 458 per sample, a level selected to optimize sample count and community coverage.

459

460 Metagenomic processing and data analysis

461

462 One-hundred eighty-five samples (n=76 Baseline, n=54 EoT, n=55 EoA, Fig. 1A), were 463 chosen among the DNA samples extracted for 16S rRNA sequencing including samples that went 464 through untargeted metabolomic analyses. Fecal samples selected had sufficient remaining 465 material for paired metagenomic and metabolomic profiling. Extracted DNA was sent to the 466 Omega Bioservices Sequencing Laboratory (Norcross, GA, USA) for shotgun metagenome 467 sequencing. DNA concentration was measured using the QuantiFluor dsDNA System on a 468 Quantus Fluorometer (Promega, Madison, WI, USA). A Kapa Biosystems HyperPlus kit (Kapa 469 Biosystems, Wilmington, MA, USA) was used for library construction. Briefly, 50 ng of genomic 470 DNA was enzymatically sheared according to the manufacturer's instructions. DNA fragment 471 ends were repaired, 3' adenylated, and ligated to adapters. The resulting adapter-ligated libraries 472 were PCR-amplified. PCR product was cleaned up from the reaction mix with magnetic 473 beads. Then, Illumina libraries were quantified using the Qubit 2.0 Fluorometer with the dsDNA 474 High Sensitivity Assay Kit (Life Technologies, Grand Island, NY) and pooled at equal molar 475 concentrations. The final pooled libraries were submitted to the Center for Advanced Technology 476 (CAT) at the University of California San Francisco. The pooled libraries were sequenced using 477 the Illumina NovaSeg 6000 in a 2×150 bp paired-end run protocol targeting minimum 60,000,000 478 raw reads per sample in total.

479

Raw sequences from all lanes were merged into a concatenated file for each sample. Raw
 FASTQ files underwent FASTQC⁵⁵ and quality and contaminant filtering using *bbTools* v38.73.
 Specifically, *bbduk* trimmed Illumina adapters, removed any PhiX contamination, filtered low-

483 auality sequences, and employed trimming after a Q score less than 15 from both the 3' and 5' 484 directions. Finally, *bbmap* removed reads mapping to the human genome using GRCh38⁵⁶ as the 485 reference database. The median number of raw reads per sample was 97,502,238 (IQR 486 30,132,152). The median number of reads following Q15 guality trimming and filtering human 487 DNA using Bbduk v38.73 (https://sourceforge.net/projects/bbmap/) was 13,367,212 (IQR 488 2,073,330). All analyses were performed on guality-filtered reads. HUMAnN 3.0 pipeline was used 489 to identify genes⁵⁷, level4ECs and functional MetaCyc pathways from the short-reads, and to 490 normalize outputs into copies per million (CPM).

491

492 Untargeted Metabolomics Analyses

493

494 Among the samples that went through shotgun-metagenome analyses, 174 (n=58 495 Baseline, n=58 EoT, n=58 EoA, Fig. 1A) matching samples were available for untargeted 496 metabolomics analyses. Two hundred milligrams of stool per sample was submitted to Metabolon 497 Inc. (Durham, NC) for ultrahigh performance liquid chromatography/tandem mass spectrometry 498 (UPLC-MS/MS) and gas chromatography-mass spectrometry (GC-MS) using their standard 499 protocol (http://www. metabolon.com/). Briefly, samples were homogenized and subjected to 500 methanol extraction then split into aliquots for analysis by ultrahigh performance liquid 501 chromatography/mass spectrometry (UHPLC/MS) in the positive (two methods) and negative (two 502 methods) mode. Metabolites were then identified by automated comparison of ion features to a 503 reference library of chemical standards followed by visual inspection for quality control (as previously described⁵⁸. Compounds were compared to Metabolon's in-house library of purified 504 505 standards, which includes more than 3,300 commercially available compounds. For statistical 506 analyses and data display, any missing values are assumed to be below the limits of detection; 507 these values were imputed with the compound minimum (minimum value imputation). For network 508 and statistical analyses, normalized, imputed, and log transformed area under curve dataset was 509 used.

510

511 In vitro Fecal Microbiome Metabolism of Peanut

512

513 Stool samples from IMPACT participants were prepared for culture as described 514 previously³⁰. Briefly, stool samples from 36 patients (D+R+, n=12, D+R-, n=12, D-R-, n=12) with 515 sufficient paired baseline and end of treatment material for the experiment were thawed on ice. 516 All fecal processing was completed under aerobic conditions. Stools were resuspended in Brain 517 Heart Infusion (BHI) media at a ratio of 10 ml/g stool prior to vigorous vertexing for 5 min and 518 filtering with a 50 µm cell strainer and storage at -80°C following 25% (volume/volume) glycerol 519 addition. A total of 10 µL of prepared feces was used to inoculate 1 mL of BHI medium 520 supplemented with 8 µL peanut extract (1/10 weight/volume in 50% glycerin, Hollister-Stier) and 521 incubated for 48 hours at 37°C under anaerobic conditions. Following 48 hours incubation, 522 microbiome cultures were centrifuged at 3,200 g for 10 min and filtered through 0.22 µm filters. 523 Ara h 2 peptide concentrations were determined using an Enzyme-Linked Immunosorbent Assay 524 (ELISA) according to manufacturer instructions (Indoor Biotechnologies, Charlottesville, VA). 525

527 Statistical analyses

528

529 Statistical analyses were performed in the R statistical programming language version 530 4.3.2. Phylogenetic diversity (Alpha diversity) was calculated in QIIME and was expressed as 531 Faith's phylogenic diversity metric, using the vegan and picante packages in R. Wilcoxon tests 532 were calculated in R. For beta-diversity (microbiome composition), distance matrices based on 533 unweighted UniFrac for 16S rDNA data and Euclidian for metabolomics dataset were generated using the *distance* function from *phyloseq* v1.30.0⁵⁹ and ordinated into two-dimensional space 534 using the *pcoa* function from the *ape* v5.3 package⁶⁰. Permutational Analysis of Variance tests 535 (PERMANOVA; R^2 and P values) were generated for independent terms with 1000 permutations 536 537 using adonis2 from the vegan package v2.5-6⁶¹. Pearson correlations and P values were 538 calculated and corrected for potential confounding factors such as age at screening, using the 539 cor.test function in R. When samples were used from multiple time points, for example, in Linear 540 Mix Effect (LME) models on longitudinal samples, only age was adjusted, and stated in figure 541 legends.

542

543 Generalized Additive Mix Model

544

545 Generalized Linear Mix Models were used on longitudinal microbiome data to determine 546 differences in microbial taxa, microbial pathways, metabolites between POIT outcome groups 547 (D+R+, D+R-, D-R-) and remission outcome (Yes or No), using Linear Model, Compound Poisson 548 Linear Model, Poisson, Negative Binomial, Zero-Inflated Negative Binomial, and Tweedie models 549 depending on data distribution. False-discovery corrections were made using the Benjamini-550 Hochberg method.

551

552 Weighted Gene Correlation Network Analyses

553

554 Co-occurrence networks of microbial pathways and metabolites were constructed using 555 weighted correlation network analysis (WGCNA) with the R package WGCNA⁶² to find modules 556 of highly interconnected, mutually exclusive metabolites. Pearson correlations were used to 557 determine inter-metabolite and inter-microbial pathway relationships, where modules are 558 composed of positively correlated metabolites. We constructed a signed network using specific 559 parameters (power = 7, reassignThreshold = 0, mergeCutHeight = 0.25), by applying hierarchical 560 clustering and topology overlap measures (TOM). The minimum module size was set to five for 561 metabolomics and one for metagenomics data. Module eigengenes (MEs) were defined as the 562 first principal component of a given module and considered as a representative measure of the 563 joint abundance profile of that module. Each module eigengenes was used to test the association 564 between its respective module and POIT-outcomes using ANOVA. Module membership was used 565 to determine the interconnectedness of each metabolite or microbial pathways to its assigned 566 module and to identify "hub" metabolite or microbial pathways: this was defined as the correlation 567 between each metabolite or microbial pathways and the Module eigengenes (MEs) (strong 568 positive values indicate high interconnectedness) as previously described⁹.

- 569
- 570

571 Multiomics Factor Analyses (MOFA2)

572

573 MOFA uses multi-omics data from the same set of samples as input and generates a 574 model that infers a set of "Factors" that best explain patterns of covariation across samples⁶³. Details of methodology can be found in the original publication⁶⁴. As input for the MOFA model, 575 576 we used untargeted metabolomics (1538 metabolites) and shotgun metagenomics datasets (518 577 features). All inputs were normalized by centralized log normalization. When fitting the model, we 578 selected for the top factors ordered by the mean fractional variance explained across omic 579 modalities (that is, factor 1 contributed the most, and factor 7 contributed the least to mean 580 fractional variation; **Extended Data Fig. 3A**). When testing factor values for statistically significant 581 differences between POIT outcome groups we used a two-tailed Mann-Whitney U-test. 582 Extended Data Fig. 3B). Top five features of metagenome and metabolome datasets from 583 significant factors were displayed (Extended Data Fig. 3C).

- 584
- 585
- 586

5 Machine Learning Model with Logistic Regression and Random Forest

587 For the predictive metabolite analysis, normalized abundance of top five metabolites from 588 Factor 2 of the MOFA2 analyses were processed with the mikropml R package (https://CRAN.Rproject.org/package=mikropml)⁶⁵. We used Random Forest (rf) and Logistic Regression functions 589 590 (glmnet) with Remission (Yes versus No) as an outcome using 50% of the samples as training 591 set and 50% as the test set. Model performances were evaluated with repeated k-fold cross-592 validation (tenfold, 10 repetitions) and parameters were tuned by choosing mtry and values 593 between 1 and the square root of the total number of variables. Model training was accomplished 594 with the caret R package (https://topepo.github.io/caret/), mtry and lambda values that determined 595 the highest model accuracy were chosen as input to Random Forest and Logistic Regression 596 analysis, respectively. Variable importance was assessed with permutations (100 iterations). Full 597 results are reported in Supplementary Table S10.

598 599

600 Availability of data and materials

601
602 The sequencing data generated from untargeted metabolomics, shotgun metagenomes
603 and amplicon sequencing for this study will be deposited to the NCBI SRA database. Additional
604 data can be shared upon request.

605

606 Acknowledgements

607

608 Research reported in this publication was supported by the National Institute of Allergy 609 and Infectious Diseases of the National Institutes of Health under Award Number UM1AI109565 610 the S.V.L's research which is funded by AI128482, and bv program AI148104, 611 UM1AI160040 and AI089473. The content is solely the responsibility of the authors and does not 612 necessarily represent the official views of the National Institutes of Health. M.Ö. is supported by 613 postdoctoral T32 fellowship 2T32DK007762-46. We thank Rebecca L. Knoll, and Elad Deiss-

614 Yehiely for their internal review of this article. We also thank Immune Tolerance Network (ITN) 615 Leadership, IMPACT study team, and study participants for making this study possible.

616

617 Author contributions

618

Conceptualization, M.Ö. and S.V.L.; methodology, M.Ö., D.L.L., C.L.G., A.L., and S.V.L.;
data analysis, M.Ö.; investigation, M.Ö. D.L.L., C.L.G., A.L., L.M.W., C.B., S.S., S.M.J., and S.V.L
writing and editing original draft, M.Ö. and S.V.L.; writing review M.Ö., C.L.G., and S.V.L.; data
visualization, M.Ö., supervision, S.V.L., funding acquisition, S.V.L.

623

624 Competing interests

625

S.V.L is a board member and consultant for the biotechnology company Siolta
Therapeutics, Inc, and holds stock in the company. She also consults for Sanofi and for the Atria
Institute of New York. M.Ö. is supported in part by National Institute of Health Training Grant T32DK007762.

630

631 Ethics Statement

This study was approved by the Office of Human Research Ethics (OHRE), University of
North Carolina, Chapel Hill on April 9, 2013. The parent study titled, "IMPACT: Oral
Immunotherapy (OIT) for Induction of Tolerance and Desensitization in Peanut-Allergic was a
randomized, double-blind, placebo-controlled, multi-center study comparing peanut oral
immunotherapy (OIT) to placebo. Informed consent was obtained from a parent or guardian of all
participants.

- 639
- 640

642 Figures and Figure Legends



643

Figure 1. a, Schematic overview of IMPACT trial fecal microbiome study⁹. b, At baseline, prior to 644 645 POIT initiation, the D+R+ group exhibit significantly lower phylogenetic diversity (α -diversity) 646 compared to either the D+R- and D-R- groups. Wilcoxon signed-rank test, n=16 (D+R+), 23 (D+R), and 8 (D-R-). c, The D+R+ group exhibit a significantly distinct gut microbiota composition 647 compared with either the D+R- or D-R- groups throughout the IMPACT trial. Linear Mixed Effect 648 649 Model (P<0.05, not significant when adjusted for age). d, e, f, Baseline gut bacterial phylogenetic 650 diversity positively correlates with baseline total IgE, peanut-specific IgE, and Ara h 2-specific IgE 651 levels, respectively. Pearson correlation, adjusted for age at screening. g, Baseline differentially abundant bacterial taxa between children who achieved remission versus no remission. 652 653 Generalized Mixed Model (P.FDR<0.05, adjusted for age). h, Baseline Peanut-IgE associated 654 bacterial taxa. Generalized Mixed Model (P.FDR<0.05). Error bars represent standard deviation.



655

656 Figure 2. a, Association between untargeted metabolomics module (UMM) eigengenes and POIT 657 outcomes (ANOVA, adjusted for age), b. Ordination of baseline secondary bile acid metabolites (n=43, R^2 = 0.10; P < 0.015, adjusted for age), PERMANOVA analyses based on Euclidian 658 659 dissimilarity metrics. c, Difference in baseline Module Eigengenes (ME), which were determined 660 based on WGCNA analyses (see Method Section) and represents a measure of the joint 661 abundance profile of a specific module, of UMM10, d, UMM15 Unconjugated BAs module, and e, 662 UMM4 between POIT-outcome groups (Wilcoxon signed-rank test). f, Z-scores of each bile acid-663 related metabolites of UMM10, g, UMM15 and, h, UMM4 in each POIT-outcome groups (D+R+, 664 D+R-, and D-R-). Blue colors represent low z-scores thus low abundance and red colors represent

high z-score and higher abundance. Error bars represent standard deviation.



666

667 Figure 3. a, Association between shotgun metagenomic module (SMM) eigengenes and POIT 668 outcomes (ANOVA, adjusted for age). b, Heatmap showing Spearman correlation results 669 between POIT-associated Untargeted Metabolomics Modules (UMMs) and Shotgun 670 Metagenomics Modules (SMMs). Asterisk "*" represents P<0.05, and double Asterisk 671 represents P<0.01. c, Factor 2 from MOFA analyses is the most significantly differential Factor 672 between POIT response groups and weighted significantly higher in no remission groups 673 compared to D+R+ group (P < 0.05, Wilcoxon signed-rank test). **d**, Top 5 microbial pathways 674 contributing the Factor 2 weight contains Gluconeogenesis and anaerobic energy metabolism 675 pathways. e, Top 5 metabolites contributing the Factor 2 weight contains bile acid metabolites. f, 676 The model's predictive ability expressed as the AUC computed from 100 times repeated five-fold 677 cross-validation. Blue line shows the average across the 100 times repeated five-fold cross-678 validations with the shaded area representing the 95% CI (mean AUC ± standard deviation). The 679 dashed diagonal line represents random chance. Error bars represent standard deviation.



medRxiv preprint doi: https://doi.org/10.1101/2024.07.15.24309840; this version posted July 15, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All fights reserved No reuse allowed without permission.

680

681 **Figure 4.** Fecal amino acid metabolite composition is distinct between POIT outcome groups at **a**, baseline $(n=43, R^2 \neq 0.08)$ $\neq 0.006$, and **b**, end of avoidance $(n=43, R^2 = 0.07; P = 0.039)$. 682 683 The colors representing the POIT outcome groups are as follows: green for D+R+, orange for 684 D+R-, blue for D-R-. c, Z-scores of all amino acid metabolite abundance in eight modulesassociated end of avoidance POIT outcome. d, Gut microbial pathways enriched in microbiome 685 686 of children who developed remission (blue bars) versus no remission (orange bars). Generalized Mixed Models (P<0.05, P.FDR>0.05). e, Fecal microbiome of children who did not achieve POIT-687 688 induced remission have a higher capacity to metabolize peanut proteins compared to children 689 who achieved POIT-induced remission (Wilcoxon signed-rank test). Data presented in this plot is 690 the average of two independent experiment. Control group refers to BHI medium supplemented 691 with peanut extract and incubated 48 h with other samples without the microbiome inoculation. 692 Error bars represent standard deviation. 693

694 **Extended Data**





Extended Data Figure 1. a, There was no significant difference in age between Placebo and 697 698 POIT groups at baseline (ANOVA, P>0.05). b, Participants who achieved POIT-induced 699 remission in the current study were significantly younger compared to participants in D+R- and 700 D-R- groups, similar to the original study (ANOVA, P<0.05). c, Phylogenetic diversity positively 701 correlates with participant age. (P < 0.05; Pearson correlation). d, Phylogenetic diversity was 702 similar between Placebo and POIT arms throughout the IMPACT trial (Linear Mix Model, adjusted 703 for age). e, D+R+ has a lower bacterial phylogenetic diversity at baseline compared to D+R- and 704 D-R- groups (P=0.043, Linear Mix Model, adjusted for age). f, Gut bacterial composition is similar 705 between Placebo and POIT groups throughout the IMPACT trial (LME n=277; Placebo=87. 706 POIT=190). g, Gut bacterial composition is distinct between POIT outcome groups (n=190; D+R+ 707 =54, D+R- =106, and D-R- =30; LME). h, Abundance of Romboutsia ilealis negatively correlates 708 with all measured peanut-specific and component specific IgE levels; Ara h 1, Arah 2, Ara h 3, 709 and Ara h 6 (Pearson correlation, adjusted for age, P<0.05). LME: Linear Mix Effect. Error bars 710 represent standard deviation. 711

712

713



716 Extended Data Figure 2. a, Difference in baseline module eigengenes (ME) of POIT outcome-717 associated untargeted metabolomics modules (Wilcoxon signed-rank test). b, Fecal bile acid 718 metabolite composition is not different between POIT-outcome groups at the end of treatment 719 and avoidance. Ordination of end of treatment and avoidance secondary bile acid metabolites, 720 PERMANOVA analyses based on Euclidian dissimilarity metrics (P> 0.05). c, The bile acid 721 modules (UMM10 and UMM15), which are significantly associated with POIT-outcome, correlate 722 with phylogenetic diversity and gut microbiome composition (P < 0.05, Pearson Correlation, 723 adjusted for age). d, Difference in end of treatment and avoidance module eigengenes (ME) of 724 POIT outcome-associated untargeted metabolomics modules (Wilcoxon signed-rank test). Error 725 bars represent standard deviation. 726

727

728



731 Extended Data Figure 3. a, MOFA2 analyses, variance explained by each omics datasets; 732 metabolomics and metagenomics. b, Seven MOFA2 factors were identified, five of which (Factors 733 1-5) were significantly different between POIT outcome groups (P < 0.05, (Wilcoxon signed-rank 734 test). c, Top five microbial pathways contributing to weight of each factor. d, Top five metabolites contributing to weight of each factor. e, Comparison of average AUC between logistic regression 735 736 and random forest models in predicting remission outcome based on five metabolites from Factor 737 2. f, Fecal metabolite composition is not different between POIT outcome groups at the end of 738 avoidance (Euclidian distance matrix. n=43, $R^2 = 0.02$; P = 0.25). Orange and blue lollipop colors 739 represent negative and positive effect on factor weight, respectively. Error bars represent 740 standard deviation. 741

- 742
- 743

Lieberman, J. A. et al. The global burden of illness of peanut allergy: A comprehensive

744 **References**

1

746		literature review. Allergy 76, 1367-1384 (2021). https://doi.org:10.1111/all.14666
747	2	Finkelman, F. D. Peanut allergy and anaphylaxis. <i>Curr Opin Immunol</i> 22, 783-788 (2010).
748		https://doi.org:10.1016/j.coi.2010.10.005
749	3	Du Toit, G. et al. Randomized Trial of Peanut Consumption in Infants at Risk for Peanut
750		Allergy. New Engl J Med 372, 803-813 (2015). https://doi.org:10.1056/NEJMoa1414850
751	4	Investigators, P. G. o. C. et al. AR101 Oral Immunotherapy for Peanut Allergy. N Engl J
752		Med 379, 1991-2001 (2018), https://doi.org:10.1056/NEJMoa1812856
753	5	Wood, R. A. Food allergen immunotherapy: Current status and prospects for the future. J
754	-	Alleray Clin Immunol 137 , 973-982 (2016), https://doi.org:10.1016/j.jaci.2016.01.001
755	6	Blumchen, K. et al. Post hoc analysis examining symptom severity reduction and symptom
756	-	absence during food challenges in individuals who underwent oral immunotherapy for
757		peanut allergy: results from three trials. Allergy Asthma Clin Immunol 19 , 21 (2023).
758		https://doi.org/10.1186/s13223-023-00757-8
759	7	Jones S M et al Efficacy and safety of oral immunotherapy in children aged 1-3 years
760	•	with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-
761		controlled study <i>Lancet</i> 399 359-371 (2022) https://doi.org/10.1016/S0140-
762		6736(21)02390-4
763	8	Yatsunenko, T, et al. Human out microbiome viewed across age and geography. Nature
764	U U	486 222-227 (2012) https://doi.org.10.1038/nature11053
765	9	Euiimura K E et al Neonatal out microbiota associates with childhood multisensitized
766	Ũ	atony and T cell differentiation Nat Med 22 1187-1191 (2016)
767		https://doi.org/10.1038/nm.4176
768	10	Ozcam M & Lynch S V The gut-airway microbiome axis in health and respiratory
769	10	diseases Nat Rev Microbiol (2024) https://doi.org/10.1038/s41579-024-01048-8
770	11	Eujimura K E et al Neonatal out microbiota associates with childhood multisensitized
771	••	atony and T cell differentiation Nat Med 22 1187-1191 (2016)
772		https://doi.org/10.1038/nm.4176
773	12	Bao R Y et al Fecal microbiome and metabolome differ in healthy and food-allergic
774	. –	twins <i>J Clin Invest</i> 131 (2021) https://doi.org/ARTN e141935 10 1172/JCI141935
775	13	Hong, X, et al. Metabolomic profiles during early childhood and risk of food allergies and
776		asthma in multiethnic children from a prospective birth cohort <i>J Alleray Clin Immunol</i>
777		(2024), https://doi.org:10.1016/i.jaci.2024.02.024
778	14	Crestani, F. et al. Untargeted metabolomic profiling identifies disease-specific signatures
779	••	in food allergy and asthma J Allergy Clin Immunol 145 897-906 (2020)
780		https://doi.org:10.1016/i.jaci.2019.10.014
781	15	Lee-Sarwar K A et al Early-life fecal metabolomics of food allergy Allergy 78 512-521
782		(2023) https://doi.org.10.1111/all 15602
783	16	Routy B et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against
784	10	epithelial tumors. Science 359, 91-97 (2018), https://doi.org/10.1126/science.aan3706
785	17	Biork J R et al Longitudinal gut microbiome changes in immune checkpoint blockade-
786		treated advanced melanoma Nat Med 30 785-796 (2024)
787		https://doi.org/10.1038/s41591-024-02803-3
788	18	Collins S L Stine J G Bisanz J F Okafor C D & Patterson A D Bile acids and
789		the out microbiota: metabolic interactions and impacts on disease. <i>Nat Rev Microbiol</i> 21
790		236-247 (2023) https://doi.org.10.1038/s41579-022-00805-x
791	19	Rimal B et al Bile salt hydrolase catalyses formation of amine-conjugated hile acids
792		Nature 626 859-863 (2024) https://doi.org.10.1038/s41586-023-06990-w
174		

793 20 Wammers, M. et al. Reprogramming of pro-inflammatory human macrophages to an anti-794 acids. Sci inflammatory phenotype Rep 255 by bile 8. (2018). 795 https://doi.org:10.1038/s41598-017-18305-x 796 21 van Best, N. et al. Bile acids drive the newborn's gut microbiota maturation. Nat Commun 797 11 (2020). https://doi.org:ARTN 3692.10.1038/s41467-020-17183-8 798 22 Larabi, A. B., Masson, H. L. P. & Bäumler, A. J. Bile acids as modulators of gut microbiota 799 composition and function. Gut Microbes 15 (2023). https://doi.org:Artn 800 2172671.10.1080/19490976.2023.2172671 801 23 Qi, X. et al. Gut microbiota-bile acid-interleukin-22 axis orchestrates polycystic ovary 802 syndrome. Nat Med 25, 1225-1233 (2019). https://doi.org:10.1038/s41591-019-0509-0 803 Stefka, A. T. et al. Commensal bacteria protect against food allergen sensitization. Proc. 24 Natl Acad Sci U S A 111, 13145-13150 (2014). https://doi.org:10.1073/pnas.1412008111 804 805 25 Diether, N. E. & Willing, B. P. Microbial Fermentation of Dietary Protein: An Important 806 Factor in Diet-Microbe-Host Interaction. Microorganisms 7 (2019). https://doi.org:ARTN 807 19.10.3390/microorganisms7010019 808 26 Barker, H. A. Amino-Acid Degradation by Anaerobic-Bacteria. Annu Rev Biochem 50, 23-809 40 (1981). https://doi.org:DOI 10.1146/annurev.bi.50.070181.000323 810 27 Guzior, D. V. & Quinn, R. A. Review: microbial transformations of human bile acids. 811 Microbiome 9, 140 (2021). https://doi.org:10.1186/s40168-021-01101-1 812 28 Brissac, T. et al. Gluconeogenesis, an essential metabolic pathway for pathogenic. Mol 813 Microbiol 98, 518-534 (2015), https://doi.org:10.1111/mmi.13139 814 29 Du Toit, G. et al. Effect of Avoidance on Peanut Allergy after Early Peanut Consumption. 815 New Engl J Med 374, 1435-1443 (2016). https://doi.org:10.1056/NEJMoa1514209 816 30 Spanogiannopoulos, P. et al. Host and gut bacteria share metabolic pathways for anti-817 cancer drua metabolism. Nat Microbiol 7, 1605-1620 (2022).818 https://doi.org:10.1038/s41564-022-01226-5 819 31 Lehmann, K. et al. Structure and stability of 2S albumin-type peanut allergens:: 820 implications for the severity of peanut allergic reactions. Biochem J 395, 463-472 (2006). 821 https://doi.org:10.1042/Bi20051728 822 32 Wahlström, A., Sayin, S. I., Marschall, H. U. & Bäckhed, F. Intestinal Crosstalk between 823 Bile Acids and Microbiota and Its Impact on Host Metabolism. Cell Metab 24, 41-50 (2016). 824 https://doi.org:10.1016/j.cmet.2016.05.005 825 33 Fiorucci, S. & Distrutti, E. Bile Acid-Activated Receptors, Intestinal Microbiota, and the 826 Treatment of Metabolic Disorders. *Trends Mol Med* **21**, 702-714 (2015). 827 https://doi.org:10.1016/j.molmed.2015.09.001 828 34 Postler, T. S. & Ghosh, S. Understanding the Holobiont: How Microbial Metabolites Affect 829 Human Health and Shape the Immune System. Cell Metab 26, 110-130 (2017). 830 https://doi.org:10.1016/i.cmet.2017.05.008 831 35 Brestoff, J. R. & Artis, D. Commensal bacteria at the interface of host metabolism and the 832 immune system. Nat Immunol 14, 676-684 (2013). https://doi.org:10.1038/ni.2640 833 Song, X. Y. et al. Microbial bile acid metabolites modulate gut RORy. regulatory T cell 36 834 homeostasis. Nature 577, 410-+ (2020). https://doi.org:10.1038/s41586-019-1865-0 835 37 Nakada, E. M. et al. Conjugated bile acids attenuate allergen-induced airway inflammation 836 and hyperresponsiveness by inhibiting UPR transducers. JCI Insight 4 (2019). 837 https://doi.org:10.1172/jci.insight.98101 838 Wu, R. L. et al. The bile acid-activated retinoic acid response in dendritic cells is involved 38 839 food allergen sensitization. Allergy 77, 483-498 (2022). in 840 https://doi.org:10.1111/all.15039 841 39 Yu, W., Freeland, D. M. H. & Nadeau, K. C. Food allergy: immune mechanisms, diagnosis 842 and immunotherapy. Rev Immunol 16, 751-765 (2016). Nat 843 https://doi.org:10.1038/nri.2016.111

- 844
 40
 Pekar, J., Ret, D. & Untersmayr, E. Stability of allergens. *Mol Immunol* **100**, 14-20 (2018).

 845
 <u>https://doi.org:10.1016/j.molimm.2018.03.017</u>
- Koidl, L., Gentile, S. A. & Untersmayr, E. Allergen Stability in Food Allergy: A Clinician's Perspective. *Curr Allergy Asthma Rep* 23, 601-612 (2023).
 https://doi.org:10.1007/s11882-023-01107-9
- Hemmings, O., Du Toit, G., Radulovic, S., Lack, G. & Santos, A. F. Ara h 2 is the dominant
 peanut allergen despite similarities with Ara h 6. *J Allergy Clin Immun* 146, 621-+ (2020).
 https://doi.org:10.1016/j.jaci.2020.03.026
- Kelly, C. P. *et al.* TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac
 Disease: A Randomized, Double-Blind, Placebo-Controlled Study. *Gastroenterology* 161, 66-+ (2021). <u>https://doi.org:10.1053/j.gastro.2021.03.014</u>
- Benne, N., ter Braake, D., Stoppelenburg, A. J. & Broere, F. Nanoparticles for Inducing
 Antigen-Specific T Cell Tolerance in Autoimmune Diseases. *Front Immunol* 13 (2022).
 https://doi.org:ARTN 864403. 10.3389/fimmu.2022.864403
- 85845Jones, S. M. *et al.* Efficacy and safety of oral immunotherapy in children aged 1-3 years859with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-860controlled study. Lancet **399**, 359-371 (2022).
- 86146DeAngelis, K. M. *et al.* Selective progressive response of soil microbial community to wild
oat roots. *Isme J* 3, 168-178 (2009). https://doi.org:10.1038/ismej.2008.103
- 47 Caporaso, J. G. *et al.* Global patterns of 16S rRNA diversity at a depth of millions of
 864 sequences per sample. *P Natl Acad Sci USA* **108**, 4516-4522 (2011).
 865 https://doi.org:10.1073/pnas.1000080107
- McCauley, K. E. *et al.* Heritable vaginal bacteria influence immune tolerance and relate to
 early-life markers of allergic sensitization in infancy. *Cell Rep Med* 3 (2022).
 https://doi.org:ARTN 100713. 10.1016/j.xcrm.2022.100713
- 869 49 Kuczynski, J. et al. Using QIIME to analyze 16S rRNA gene sequences from microbial 870 communities. Protoc Microbiol Chapter 1, Unit 1E Curr 5 (2012). 871 https://doi.org:10.1002/9780471729259.mc01e05s27
- 87250Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon
data. Nat Methods 13, 581-583 (2016). https://doi.org:10.1038/nmeth.3869
- 87451Quast, C. et al. The SILVA ribosomal RNA gene database project: improved data875processing and web-based tools. Nucleic Acids Res 41, D590-596 (2013).876https://doi.org:10.1093/nar/gks1219
- Schliep, K. P. phangorn: phylogenetic analysis in R. *Bioinformatics* 27, 592-593 (2011).
 https://doi.org:10.1093/bioinformatics/btq706
- Schliep, K., Potts, A. J., Morrison, D. A. & Grimm, G. W. Intertwining phylogenetic trees and networks. *Methods Ecol Evol* 8, 1212-1220 (2017). <u>https://doi.org:10.1111/2041-210x.12760</u>
- Wright, E. S. Using DECIPHER v2.0 to Analyze Big Biological Sequence Data in R. *R J*883 8, 352-359 (2016).
- 55 Davis, M. P. A., van Dongen, S., Abreu-Goodger, C., Bartonicek, N. & Enright, A. J.
 Kraken: A set of tools for quality control and analysis Of high-throughput sequence data. *Methods* 63, 41-49 (2013). <u>https://doi.org:10.1016/j.ymeth.2013.06.027</u>
- Schneider, V. A. *et al.* Evaluation of GRCh38 and de novo haploid genome assemblies
 demonstrates the enduring quality of the reference assembly. *Genome Res* 27, 849-864
 (2017). <u>https://doi.org:10.1101/gr.213611.116</u>
- Beghini, F. *et al.* Integrating taxonomic, functional, and strain-level profiling of diverse
 microbial communities with bioBakery 3. *Elife* **10** (2021). <u>https://doi.org:ARTN</u> e65088.
 10.7554/eLife.65088

- 58 DeHaven, C. D., Evans, A. M., Dai, H. P. & Lawton, K. A. Organization of GC/MS and LC/MS metabolomics data into chemical libraries. *J Cheminformatics* 2 (2010).
 https://doi.org:Artn 9. 10.1186/1758-2946-2-9
- 896 59 McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive
 897 Analysis and Graphics of Microbiome Census Data. *Plos One* 8 (2013).
 898 <u>https://doi.org:ARTN</u> e61217. 10.1371/journal.pone.0061217
- 89960Paradis, E. & Schliep, K. ape 5.0: an environment for modern phylogenetics and
evolutionary analyses in R. *Bioinformatics* **35**, 526-528 (2019).901https://doi.org:10.1093/bioinformatics/bty633
- 902
 61
 Dixon, P. VEGAN, a package of R functions for community ecology. J Veg Sci 14, 927

 903
 930 (2003). https://doi.org:Doi 10.1658/1100-9233(2003)014[0927:Vaporf]2.0.Co;2
- 90462Langfelder, P. & Horvath, S. WGCNA: an R package for weighted correlation network905analysis. BMC Bioinformatics 9, 559 (2008). https://doi.org/10.1186/1471-2105-9-559
- 90663Thiele Orberg, E. et al. Bacteria and bacteriophage consortia are associated with907907protective intestinal metabolites in patients receiving stem cell transplantation. Nat Cancer9085, 187-208 (2024). https://doi.org:10.1038/s43018-023-00669-x
- 909 Argelaguet, R. et al. Multi-Omics Factor Analysis-a framework for unsupervised integration 64 910 Syst multi-omics data 14. e8124 of sets. Mol Biol (2018). 911 https://doi.org:10.15252/msb.20178124
- 912 65 Topcuoglu, B. D. *et al.* mikropml: User-Friendly R Package for Supervised Machine 913 Learning Pipelines. *J Open Source Softw* **6** (2021). https://doi.org:10.21105/joss.03073
- 914